Paul Tudor Jones Alector, Inc. Transaction History

Tudor Investment Corp Et Al

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.19 - $6.23 $85,212 - $126,699	20,337 New	20,337 $92,000
Q4 2022 Feb 14, 2023	SELL	$6.88 - $9.55 $48,359 - $67,126	-7,029 Reduced 19.06%	29,850 $276,000
Q3 2022 Nov 14, 2022	BUY	$8.19 - $13.2 $302,039 - $486,802	36,879 New	36,879 $349,000
Q2 2022 Aug 15, 2022	SELL	$7.65 - $14.24 $141,578 - $263,539	-18,507 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$13.02 - $20.78 $240,961 - $384,575	18,507 New	18,507 $264,000
Q4 2021 Feb 14, 2022	SELL	$19.35 - $25.54 $294,390 - $388,565	-15,214 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$21.65 - $39.49 $81,598 - $148,837	3,769 Added 32.93%	15,214 $347,000
Q2 2021 Aug 16, 2021	BUY	$15.5 - $22.48 $177,397 - $257,283	11,445 New	11,445 $238,000

168

57.8M

146K

90.8K

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $159M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.